Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Cirrhosis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    September 2022
  1. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    PubMed    


  2. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    PubMed     Abstract available


    July 2022
  3. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    PubMed     Abstract available


  4. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    PubMed    


  5. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    PubMed     Abstract available


    June 2022
  6. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.
    PubMed    


    May 2022
  7. GORGULU E, Gu W, Trebicka J, Mucke VT, et al
    Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?
    Gut. 2022;71:1036-1038.
    PubMed    


  8. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    PubMed     Abstract available


    March 2022
  9. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.
    PubMed    


  10. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    PubMed     Abstract available


    February 2022
  11. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.
    PubMed    


    January 2022
  12. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.
    PubMed    


    December 2021
  13. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    PubMed     Abstract available


  14. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.
    PubMed    


  15. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    PubMed     Abstract available


    October 2021
  16. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    PubMed     Abstract available


  17. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    PubMed     Abstract available


    August 2021
  18. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    PubMed     Abstract available


    July 2021
  19. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    PubMed     Abstract available


    June 2021
  20. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    PubMed    


    May 2021
  21. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    PubMed    


    April 2021
  22. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    PubMed     Abstract available


    March 2021
  23. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.
    PubMed    


    February 2021
  24. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    PubMed     Abstract available


  25. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    PubMed     Abstract available


    January 2021
  26. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    PubMed    


    October 2020
  27. BAYO J, Fiore EJ, Dominguez LM, Cantero MJ, et al
    Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Gut. 2020 Oct 26. pii: gutjnl-2020-321454. doi: 10.1136/gutjnl-2020-321454.
    PubMed     Abstract available


  28. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.
    PubMed    


  29. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    PubMed     Abstract available


  30. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    PubMed     Abstract available


  31. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.
    PubMed    


    September 2020
  32. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    PubMed     Abstract available


  33. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available


    July 2020
  34. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.
    PubMed    


    June 2020
  35. THANGAPANDI VR, Knittelfelder O, Brosch M, Patsenker E, et al
    Loss of hepatic Mboat7 leads to liver fibrosis.
    Gut. 2020 Jun 26. pii: gutjnl-2020-320853. doi: 10.1136/gutjnl-2020-320853.
    PubMed     Abstract available


  36. BREITKOPF-HEINLEIN K, Syn WK
    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.
    PubMed    


  37. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    PubMed     Abstract available


  38. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    PubMed     Abstract available


    March 2020
  39. SCHATTENBERG JM
    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.
    PubMed    


    February 2020
  40. LOOMBA R, Adams LA
    Advances in non-invasive assessment of hepatic fibrosis.
    Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.
    PubMed     Abstract available


    January 2020
  41. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available


    December 2019
  42. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available


    October 2019
  43. CHEN Y, Lin XY
    Are the 5-hydroxymethylcytosine-based wd-scores really superior over alpha-fetoprotein for the early diagnosis of hepatocellular carcinoma?
    Gut. 2019 Oct 25. pii: gutjnl-2019-319853. doi: 10.1136/gutjnl-2019-319853.
    PubMed    


    September 2019
  44. MARTI-RODRIGO A, Alegre F, Moragrega AB, Garcia-Garcia F, et al
    Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
    Gut. 2019 Sep 17. pii: gutjnl-2019-318372. doi: 10.1136/gutjnl-2019-318372.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: